Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.45 |
| ▸ | AXL | P30530 | 3/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448723 | 0.94 | LCK (0.48) | MAPK1FLT3KITMALT1AXL | |
| SCHEMBL3450656 | 0.93 | MAPK1 (0.49) | MAPK1MALT1AXLSTK17ASTK17B | |
| SCHEMBL3452720 | 0.88 | MAPK1 (0.51) | MAPK1AXLSTK17ASTK17BEGFR | |
| SCHEMBL3449764 | 0.88 | MAPK1 (0.51) | MAPK1AXLSTK17ASTK17BEGFR | |
| SCHEMBL3449638 | 0.87 | MAPK1 (0.50) | MAPK1AXLSTK17ASTK17BEGFR | |
| SCHEMBL3450023 | 0.87 | MAPK1 (0.50) | MAPK1AXLSTK17ASTK17BEGFR | |
| SCHEMBL3451168 | 0.87 | MAPK1 (0.44) | MAPK1MALT1AXLSTK17ASTK17B | |
| SCHEMBL3448492 | 0.86 | MALT1 (0.53) | MALT1EGFRHTT | |
| SCHEMBL3450611 | 0.86 | SYK (0.46) | MAPK1MALT1AXLEGFRERBB2 | |
| SCHEMBL3450288 | 0.85 | ABL1 (0.46) | MAPK1MALT1AXLEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | MAPK1 2905/4885FLT3 564/4885KIT 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.